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Abstract
Hypoglycemia and neuroglucopenia stimulate AMP-activated protein kinase (AMPK) activity in the hypothalamus and this
plays an important role in the counterregulatory responses, i.e. increased food intake and secretion of glucagon,
corticosterone and catecholamines. Several upstream kinases that activate AMPK have been identified including Ca
2+/
Calmodulin-dependent protein kinase kinase (CaMKK), which is highly expressed in neurons. However, the involvement of
CaMKK in neuroglucopenia-induced activation of AMPK in the hypothalamus has not been tested. To determine whether
neuroglucopenia-induced AMPK activation is mediated by CaMKK, we tested whether STO-609 (STO), a CaMKK inhibitor,
would block the effects of 2-deoxy-D-glucose (2DG)-induced neuroglucopenia both ex vivo on brain sections and in vivo.
Preincubation of rat brain sections with STO blocked KCl-induced a1 and a2-AMPK activation but did not affect AMPK
activation by 2DG in the medio-basal hypothalamus. To confirm these findings in vivo, STO was pre-administrated
intracerebroventricularly (ICV) in rats 30 min before 2DG ICV injection (40 mmol) to induce neuroglucopenia. 2DG-induced
neuroglucopenia lead to a significant increase in glycemia and food intake compared to saline-injected control rats. ICV pre-
administration of STO (5, 20 or 50 nmol) did not affect 2DG-induced hyperglycemia and food intake. Importantly, activation
of hypothalamic a1 and a2-AMPK by 2DG was not affected by ICV pre-administration of STO. In conclusion, activation of
hypothalamic AMPK by 2DG-induced neuroglucopenia is not mediated by CaMKK.
Citation: Kawashima J, Alquier T, Tsuji Y, Peroni OD, Kahn BB (2012) Ca
2+/Calmodulin-Dependent Protein Kinase Kinase Is Not Involved in Hypothalamic AMP-
Activated Protein Kinase Activation by Neuroglucopenia. PLoS ONE 7(5): e36335. doi:10.1371/journal.pone.0036335
Editor: Xin-Yun Lu, University of Texas Health Science Center at San Antonio, United States of America
Received February 21, 2012; Accepted April 3, 2012; Published May 10, 2012
Copyright:  2012 Kawashima et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health Grants P01 DK56116 and P30 DK57521, an ADA Mentor-Based Fellowship, a grant from the
Picower Foundation (BBK), and an ADA-EASD fellowship grant (TA). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: TA is a PLoS ONE Editorial Board Member. This does not alter the author’s adherence to all PLoS ONE policies on sharing data and
materials. The other co-authors have declared that no competing interests exist.
* E-mail: bkahn@bidmc.harvard.edu
¤a Current address: Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
¤b Current address: Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l9Universite de Montreal (CRCHUM), and Department of
Medicine, University of Montreal, Montreal, Quebec, Canada
¤c Current address: Metabolic Disease Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Kanagawa, Japan
. These authors contributed equally to this work.
Introduction
The AMP-activated protein kinase (AMPK) is an evolutionarily
conserved enzyme that senses cellular energy status and regulates
fuel availability [1]. AMPK acts as an energy and glucose sensor in
the hypothalamus to control food intake and metabolism in
peripheral tissues. AMPK is a heterotrimeric protein consisting of
catalytic a- and regulatory b- and c- subunits. AMPK is activated
allosterically by increases in the AMP/ATP ratio as well as by
phosphorylation on Thr
172 by upstream kinases [1] while ADP
allosterically protects AMPK from dephosphorylation and inacti-
vation [2,3].
Presently, three upstream AMPK Kinases (AMPKK) have been
identified, Liver Kinase B1 (LKB1), Ca
2+/Calmodulin-dependent
protein kinase kinase (CaMKK) and transforming growth factor-
beta-activated kinase (TAK1) [4,5,6]. The CaMKK family is
composed of two isoforms CaMKKa and CaMKKb. Since the
original findings that CaMKKb phosphorylates and activates
AMPK via an AMP-independent manner, which is triggered
instead by a rise in intracellular Ca
2+ concentration [5,7,8], many
studies have demonstrated that AMPK is activated by CaMKK in
peripheral tissues or cells in response to nutrients, drugs, or
physiological stimulation [9,10,11,12,13]. CaMKKa and
CaMKKb are highly expressed throughout the brain including
in several areas controlling food intake and neuroendocrine
function (i.e. hypothalamus and hindbrain) [14,15] suggesting that
CaMKKs could play an important role in the regulation of AMPK
activity and control of energy balance. In line with this, recent data
demonstrated that CaMKKb is involved in ghrelin-induced
AMPK activation in the hypothalamus as well as in the orexigenic
action of ghrelin [15].
Several studies have demonstrated that hypothalamic AMPK is
regulated by blood glucose levels. Peripheral or central hypergly-
cemia inhibits AMPK in several hypothalamic nuclei, the arcuate
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medial hypothalamus (DMH), the paraventricular nucleus (PVN)
and the lateral hypothalamus (LH) [16,17] whereas insulin-
induced hypoglycaemia or 2-deoxy-D-glucose (2DG)-induced
glucopenia activates AMPK [16,18,19]. Recent studies suggest
that activation of hypothalamic AMPK may be required for the
counterregulatory response to hypoglycemia [18,19,20]. More-
over, hypothalamic AMPK activation causes an increase in food
intake, which may act to restore depleted energy stores [16,18,19].
However, it is still unclear which upstream kinases are involved in
hypothalamic AMPK activation in response to metabolic
challenges such as neuroglucopenia.
The primary goal of the present study was to assess whether
CaMKKs are involved in the hypothalamic activation of AMPK
by neuroglucopenia. In this study, we incubated brain slices ex-vivo
in the presence of KCl (to induce neuronal depolarization) or 2DG
with or without STO-609, an inhibitor of CaMKKs. Furthermore,
we investigated the effect of STO-609 on the counterregulatory
responses to neuroglucopenia induced in vivo by intracerebroven-
tricular (ICV) administration of 2DG.
Materials and Methods
Animals
Male Sprague-Dawley rats (Charles River Laboratories, Wil-
mington, MA) were housed one per cage with a constant
temperature (21–23uC) and a 14:10 h light/dark cycle with access
to food and water ad libitum. All study protocols were approved by
the Institutional Animal Care and Use Committee (Beth Israel
Deaconess Medical Center).
Western Blot Analysis
Tissue lysates were prepared as described previously [19]. The
total amount of CaMKKa and CaMKKb protein in hypotha-
lamic nuclei and different brain areas was determined using 10%
SDS acrylamide gels and antibodies specific for CaMKKa or
CaMKKb (Santa Cruz Biotechnology, Santa Cruz, CA).
Preparation and Incubation of Rat Brain Slices
Coronal hypothalamic slices were prepared from 7-week-old
male Sprague-Dawley rats. Following decapitation, the brain was
rapidly removed and immersed in high-Mg
2+ but Ca
2+-free, ice-
cold artificial cerebrospinal fluid (aCSF) of the following compo-
sition (mM): NaCl, 114; KCl, 3; NaH2PO4, 1.25; MgSO4,1 ;
MgCl2, 10; Hepes-Na (pH 7.4), 10; NaHCO3, 26; D-glucose, 10;
pH 7.4; bubbled with 95% O2-5% CO2. Three hypothalamic
sections, each 400 mm thick, were cut from each rat using a
Vibratome while being continuously immersed in ice-cold aCSF.
Hypothalamic sections were maintained in an incubation chamber
at room temperature for 30 min and then at 36uC for 2 hr with
standard aCSF (2 mM CaCl2 instead of 10 mM MgCl2). After the
pre-incubation period, sections were pre-treated for 30 min with
either vehicle (100 mM NaOH) or STO-609 (25 mM, Tocris,
Ellisville, MO). KCl (30 mM) was added in the experimental
chambers for 5 min to induce neuronal depolarization. Glucope-
nia was induced by incubating the sections with 10 mM D-glucose
or 10 mM 2DG for 15 min. After the incubation, the medio-basal
region of the hypothalamus including the ARC and VMH/DMH
was dissected as described [19] and snap frozen in liquid nitrogen.
Samples were stored at 280uC until subsequent homogenization
and AMPK activity assay. Each treatment was repeated with
sections from at least five different rats.
Lateral Ventricle Cannulation
Male Sprague-Dawley rats (Charles River), weighing 300–
350 g, were stereotaxically implanted with a 26-gauge stainless
steel cannula (Plastics One, Roanoke, VA) aimed at the right
lateral ventricle as described previously [19].
Intracerebroventricular (ICV) Injections
For this experiment, fed rats were assigned to three different
groups. A control group was injected ICV with saline 30 min
before an ICV saline injection (Saline-Saline). The Saline-2DG
group was injected ICV with saline 30 min prior to an ICV 2DG
injection. The STO-2DG group was injected ICV with STO-609
30 min before the ICV injection of 2DG. The ICV injections were
performed as follow. The ICV injections of saline or STO-609 (5,
20 or 50 nmol), at a speed of 0.5 ml/min in 10 min using
microdialysis pumps, were made using a 31-gauge injector (equal
length of the cannula). 30 min after saline or STO-609 ICV
injection, saline or 7 mg (40 mmol) of 2DG was injected ICV at a
speed of 10 ml in 3 min using microdialysis pumps [19]. The
injector was kept in place for an additional minute before it was
removed and replaced by the dummy cannula. Plasma glucose was
measured using the One-Touch Ultra glucometer from the tail
vein vessels before (0 min) and 60 min after 2DG ICV injection.
One hour after 2DG injection, a pre-weighed quantity of food was
introduced in the cage and food intake was measured over 1 hour.
For the AMPK activity experiments, the animals received saline or
STO-609 (50 nmol) ICV injections as described above and were
killed by decapitation 10 minutes after saline or 2DG ICV
injection. Immediately after the decapitation, ARC and VMH/
DMH were dissected as described [19] and frozen in liquid
nitrogen.
AMPK Activity Assay
AMPK activity was measured in hypothalamic regions by
immunoprecipitation of a1-AMPK or a2-AMPK from hypotha-
lamic regions (50 mg) with specific antibodies against the catalytic
a1-subunit or a2-subunit (generous gift from Dr. D. Carling)
bound to protein-G/Sepharose beads. Kinase activity was
measured using synthetic ‘‘SAMS’’ peptide and [c-
32P] ATP as
described previously [17].
Data Analysis
All data are presented as means 6 SEM. Significance is set at
p,0.05. Analyses of a1-AMPK or a2-AMPK activities in
hypothalamic samples were performed by two-way ANOVA.
Comparisons of a1-AMPK or a2-AMPK activity in hypothalamic
nuclei after 2DG injection in vivo were made by unpaired t-test.
Analyses of glycemia and food intake were performed using two-
way ANOVA.
Results
Expression of CaMKKa and CaMKKb in Hypothalamic
Nuclei
In agreement with previous studies performed in rats [14,19],
CaMKKa and CaMKKb proteins were detected in all hypotha-
lamic nuclei analyzed and in hindbrain. However, the protein
levels in these regions were lower than the levels in cortex and
hippocampus (Fig. 1). CaMKKa and CaMKKb were undectable
in liver protein extracts.
AMPK Activation by 2DG Is CaMKK Independent
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Depolarization is Blocked by STO-609 in Brain Sections
Ex-vivo
Brain sections, pre-incubated with either vehicle
(100 mM NaOH) or STO-609 (25 mM) for 30 min, were treated
with or without KCl (30 mM) for 5 min to induce neuronal
depolarization.STO-609 treatment did not affect basal a1-AMPK
or a2-AMPK activities (Fig. 2A and B) in the medio-basal
hypothalamus. K
+-induced depolarization, which increases intra-
cellular calcium and activates CaMKKs pathways in cells [5,7,8],
resulted in a 2.2 fold-increase in a1-AMPK and a 2.1 fold-increase
in a2-AMPK activity in the hypothalamus. STO-609 pre-
treatment partially inhibited (66%) K
+-induced a1 AMPK
activation (Fig. 2A) and totally inhibited K
+-induced a2 AMPK
activation (Fig. 2B). These data are in agreement with a previous
study [5].
Hypothalamic AMPK activation by 2DG is not inhibited
by STO-609 in a brain section preparation. After pre-
incubation with either vehicle or STO-609 (25 mM) for 30 min,
brain sections were incubated in presence of 10 mM D-glucose or
10 mM 2DG for 15 min. 2DG treatment induced a 2 fold-
increase in a1-AMPK activity and a 3.2 fold-increase in a2-
AMPK in the hypothalamus (Fig. 2C and 2D). In contrast to K
+-
induced AMPK activation, 2DG-induced a1 and a2-AMPK
activation were not inhibited by STO-609 pre-treatment (Fig. 2C
and 2D).
Counterregulatory responses to 2DG-induced
neuroglucopenia are not affected by STO-609. ICV injec-
tion of 2DG was performed to induce glucopenia specifically in the
brain [19]. The main advantage of using ICV 2DG compared
with insulin-induced hypoglycemia is that the 2DG effects are
acutely localized to the brain so that one can study signalling in the
hypothalamus in the absence of other potentially confounding
systemic effects that could modify the effects in the brain. We used
a 2DG concentration known to induce glucopenia that is rapidly
followed by stimulation of food intake and counterregulatory
responses including increased plasma corticosterone and glucagon
levels [19]. Rats were divided in to 3 groups, Saline-Saline group
(control), Saline-2DG group (Saline-2DG) and STO-2DG group
(2DG-STO) as described in ‘‘Materials and Methods’’. To
determine the optimal dose of STO609 ICV, we injected rats
with different doses of STO (5, 20 or 50 nmol) in the lateral
ventricle 30 min before 2DG ICV. Basal glycemia (0 min) was not
different among the three animal groups (Fig 3A). ICV 2DG
elicited a significant increase in glycemia 60 min after the injection
in the Saline-2DG group compared to the Saline-Saline group
(Fig 3A). Consistent with the glycemia data, 2DG injection
induced a 5-fold increase in food intake over 1 h compared with
the Saline-Saline group (Fig 3B). In the STO-2DG group, ICV
STO-609 pre-treatment (5, 20 or 50 nmol) did not affect the 2DG-
induced increase in glycemia 60 min after 2DG injection (Fig 3A)
nor the 2DG-induced increase in 1-h food intake compared to the
Saline-2DG group (Fig 3B).
AMPK Activation by Neuroglucopenia is not Affected by
STO-609
Both a1 and a2-AMPK activities were measured in ARC and
VMH/DMH hypothalamic areas 10 min after 2DG injection in
rats pre-treated with saline or STO-609 (50 nmol). 2DG ICV
injection elicited a 40% increase in both a1 and a2-AMPK
activities in the ARC and a 25% increase of a1 and a2-AMPK
activities in the VMH/DMH 10 min after the injection compared
to Saline-Saline group (Fig 4A and B) as described previously [19].
However, STO-609 pre-treatment did not affect the 2DG-induced
a1 and a2-AMPK activation in the ARC or VMH/DMH (Fig. 4A
and B).
Discussion
AMPK is activated allosterically by increases in the AMP/ATP
ratio as well as by phosphorylation on Thr
172 by upstream kinases
including LKB1 and CaMKKs [1] while ADP prevents its
dephosphorylation and inactivation [2,3]. Several studies have
recently suggested a physiologic role for CaMKKa and CaMKKb
in AMPK activation in mamalian cells [5,7,8,15]. CaMKKb null
mice ate less and accumulated less body weight and fat stores
supporting the role of central CaMKKb in the control of energy
balance [15]. In the central nervous system, CaMKKs are
involved in different processes including brain development,
neuron survival and long-term memory. However, the hypothesis
that CaMKKs could be involved in AMPK activation in the
hypothalamus in response to glucopenia in vivo has not been tested.
In this study, we demonstrate that hypothalamic AMPK activation
by neuronal depolarization is CaMKKs dependent whereas
glucopenia-induced AMPK activation in the same hypothalamic
regions does not involve the CaMKK pathway.
Consistent with a previous report [14], we showed that both
CaMKKa and CaMKKb are expressed in several hypothalamic
nuclei as well as the hindbrain. However, CaMKKa and
CaMKKb expression levels in those areas are lower compared
to cortical or hippocampal expression levels. Using a brain section
model ex-vivo, we demonstrated that neuronal K
+-induced
depolarization triggers hypothalamic AMPK activation and that
pre-treatment with the CaMKK inhibitor STO-609 prevents
depolarization-induced a1 and a2-AMPK activation in the medio-
Figure 1. CaMKKa and CaMKKb protein expression in hypothalamic nuclei and non-hypothalamic brain areas. Tissue lysates (40 mg
protein) were subjected to Western blotting with anti-CaMKKa or anti-CaMKKb antibodies (Santa Cruz) as described in ‘‘Materials and Methods’’. Hip;
hippocampus, Arc; arcuate nucleus, VMH/DMH; ventromedial hypothalamus/dorsomedial hypothalamus, PVN; paraventricular nucleus, LH; lateral
hypothalamus, HB; hindbrain.
doi:10.1371/journal.pone.0036335.g001
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a previous report showing that CaMKK inhibition by STO-609
on brain slices inhibits depolarization-induced AMPK activation
[5]. However, in that study total AMPK activity (a1 and a2-
AMPK) was measured in a whole brain slice protein extract. Thus,
we demonstrated here that CaMKK pathway inhibition by STO-
609 blocks the K
+-induced activation of both a1 and a2-AMPK in
hypothalamic nuclei (ARC and VMH/DMH).
To determine whether the CaMKK pathway is also required
for hypothalamic AMPK activation during glucose deprivation,
brain slices were incubated in the presence of the glucoprivic
agent 2DG to induce glucopenia. We previously reported that
2DG-induced glucopenia in vivo rapidly activates AMPK in
several hypothalamic nuclei including the ARC and VMH/
DMH [19]. In brain sections ex-vivo, 2DG treatment triggers
activation of both a1 and a2-AMPK in the hypothalamus.
However, in contrast to K
+-induced activation of AMPK, STO-
609 did not inhibit activation of hypothalamic a1o ra2-AMPK
in response to 2DG. These data strongly suggest that activation
of hypothalamic AMPK by glucoprivation is not CaMKK
dependent. Despite the fact that both stimuli activate AMPK,
our results suggest that the signalling pathways leading to
AMPK activation are different. This difference could be
explained in part by the nature of the intracellular signals
modulated by 2DG and K
+-induced depolarization. Indeed, it is
well established that both K
+-induced depolarization and 2DG-
Figure 2. STO-609 blocks AMPK activation induced by KCl but not by 2DG in hypothalamus. Brain sections, pre-incubated with either
vehicle (100 mM NaOH) or STO-609 (25 mM) for 30 min, were treated with or without KCl (30 mM) for 5 min (A and B). Brain sections, pre-incubated
with either vehicle (100 mM NaOH) or STO-609 (25 mM), an inhibitor of CaMKKs, for 30 min were treated with D-glucose (10 mM) or 2DG (10 mM) for
15 min (C and D). a1 (A and C) or a2 AMPK (B and D) activities were measured in Arcuate-VMH/DMH samples. n=526 rats per group. Data are means
6 SEM. *p,0.05 vs. control, #p,0.05 vs. KCl alone.
doi:10.1371/journal.pone.0036335.g002
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in neuronal cells [21]. However, K
+-induced depolarization does
not affect the ATP/AMP ratio [5] whereas 2DG increases the
ATP/AMP ratio in neuronal cells [22]. From these observations
and our data, we hypothetize that the increase in the ATP/
AMP ratio induced by 2DG activates AMPK independently of
Figure 3. STO-609 does not affect counter-regulatory responses to neuroglucopenia in vivo. Saline or STO-609 (5, 20 or 50 nmol) was
injected ICV in fed rats 30 min before ICV injection of saline or 2DG (40 mmol) as described in ‘‘Materials and Methods’’. Glycemia (A) and 1-h food
intake (B) were measured. n=529 rats per group. Data are means 6 SEM. *p,0.05 vs. saline-saline group.
doi:10.1371/journal.pone.0036335.g003
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might be involved in 2DG activation of AMPK such as LKB1
[23].
To support our ex-vivo findings on brain sections, we tested the
effect of the CaMKK inhibitor in vivo on the counterregulatory
responses to neuroglucopenia induced by 2DG. We previously
reported that 2DG ICV injection in rat brain rapidly activates the
counterregulatory responses (increases in food intake and counter-
regulatory hormones) and triggers both a1 and a2-AMPK
activation in several hypothalamic nuclei (i.e. ARC and VMH/
DMH) [19]. We and others also showed that hypothalamic
AMPK activation by neuroglucopenia or insulin-induced hypo-
glycemia is required for the counterregulatory responses
[18,19,20]. As demonstrated, ICV 2DG induces counterregulatory
responses to neuroglucopenia resulting in marked increases in
blood glucose levels and food intake. However, these responses
were not affected by pre-treatment with STO-609. Consistent with
these findings, 2DG-induced activation of a1 and a2-AMPK in
ARC and VMH/DMH after 2DG injection was not affected by
prior treatment with STO-609. These data suggest that the
CaMKK pathway is not involved in the activation of hypotha-
lamic AMPK and the couterregulatory response to glucopenia.
The STO-609 concentrations used in vivo were extrapolated from
the concentrations used ex-vivo on brain slices (based on a rat CSF
volume of 150 ml). Because STO-609 is a cell-permeable inhibitor,
we used a 10-fold range of STO-609 doses. We can not rule out
the possibility that STO-609 only partially inhibited CaMKKs
when injected ICV. However, our ex-vivo data combined with the
in vivo findings strongly suggest that AMPK activation in the
hypothalamus by glucopenia is not CaMKKs dependent. Thus,
we conclude that the signaling pathways involved in AMPK
activation in the hypothalamus are dictated by the nature of the
stimulus and the intracellular signals involved (intracellular
calcium vs. ATP/AMP and ATP/ADP ratios). These findings
are supported by the work of Anderson et al. showing that the
orexigenic action of ghrelin, which elicits increases in neuronal
intracellular calcium, is absent in CaMKKb null mice whereas the
orexigenic action of 2DG was not affected [15]. However, the
counterregulatory response per se (hyperglycemia) to 2DG was not
measured in that study. Therefore, our results also demonstrate
that 2DG-induced hyperglycemia is CaMKK independent.
In summary, the CaMKKs inhibitor STO-609 did not block
hypothalamic AMPK activation induced by glucopenia in rats or
in brain slices ex vivo, whereas the inhibitor blunted the activation
of hypothalamic AMPK by K
+-induced depolarization of brain
slices ex vivo. ICV administration of STO-609 in vivo did not affect
the counterregulatory responses to neuroglucopenia and AMPK
activation induced by glucopenia. We conclude that AMPK is
activated in hypothalamic nuclei by neuroglucopenia via a
CaMKK-independent pathway.
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